DURECT Corporation (DRRX)
USD 0.75
(5.66%)
USD 0.75
(5.66%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 43.71 Million USD | -17.17% |
| 2022 | 52.77 Million USD | 14.0% |
| 2021 | 46.29 Million USD | 12.04% |
| 2020 | 41.32 Million USD | -7.3% |
| 2019 | 44.57 Million USD | 17.54% |
| 2018 | 37.92 Million USD | -15.31% |
| 2017 | 44.77 Million USD | 8.94% |
| 2016 | 41.09 Million USD | 14.54% |
| 2015 | 35.88 Million USD | 3.37% |
| 2014 | 34.71 Million USD | 9.67% |
| 2013 | 31.65 Million USD | -2.19% |
| 2012 | 32.36 Million USD | -32.06% |
| 2011 | 47.62 Million USD | -6.89% |
| 2010 | 51.15 Million USD | 2.2% |
| 2009 | 50.04 Million USD | -26.83% |
| 2008 | 68.4 Million USD | 31.56% |
| 2007 | 51.99 Million USD | 3.81% |
| 2006 | 50.08 Million USD | 21.02% |
| 2005 | 41.38 Million USD | 16.8% |
| 2004 | 35.43 Million USD | 15.47% |
| 2003 | 30.68 Million USD | -28.75% |
| 2002 | 43.06 Million USD | 11.87% |
| 2001 | 38.49 Million USD | 55.94% |
| 2000 | 24.68 Million USD | 154.06% |
| 1999 | 9.71 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 7.25 Million USD | -12.22% |
| 2024 Q2 | 5.21 Million USD | -28.06% |
| 2023 Q2 | 11.77 Million USD | -7.21% |
| 2023 Q1 | 12.68 Million USD | -11.26% |
| 2023 Q3 | 10.98 Million USD | -6.66% |
| 2023 Q4 | 8.26 Million USD | -24.79% |
| 2023 FY | 43.71 Million USD | -17.17% |
| 2022 Q2 | 12.76 Million USD | 6.89% |
| 2022 FY | 52.77 Million USD | 14.0% |
| 2022 Q3 | 13.76 Million USD | 7.79% |
| 2022 Q4 | 14.29 Million USD | 3.88% |
| 2022 Q1 | 11.94 Million USD | -7.6% |
| 2021 Q2 | 10.6 Million USD | -7.87% |
| 2021 Q4 | 12.92 Million USD | 14.83% |
| 2021 Q1 | 11.5 Million USD | 13.98% |
| 2021 FY | 46.29 Million USD | 12.04% |
| 2021 Q3 | 11.25 Million USD | 6.21% |
| 2020 Q3 | 10.48 Million USD | 3.59% |
| 2020 Q4 | 10.09 Million USD | -3.75% |
| 2020 Q1 | 11.15 Million USD | -15.78% |
| 2020 FY | 41.32 Million USD | -7.3% |
| 2020 Q2 | 10.12 Million USD | -9.25% |
| 2019 Q1 | 9.7 Million USD | 2.96% |
| 2019 Q3 | 11.74 Million USD | 18.9% |
| 2019 Q2 | 9.87 Million USD | 1.76% |
| 2019 FY | 44.57 Million USD | 17.54% |
| 2019 Q4 | 13.24 Million USD | 12.82% |
| 2018 Q4 | 9.42 Million USD | 0.15% |
| 2018 FY | 37.92 Million USD | -15.31% |
| 2018 Q3 | 9.41 Million USD | 5.33% |
| 2018 Q2 | 8.93 Million USD | -11.93% |
| 2018 Q1 | 10.14 Million USD | 2.41% |
| 2017 Q4 | 9.9 Million USD | -13.97% |
| 2017 FY | 44.77 Million USD | 8.94% |
| 2017 Q1 | 10.59 Million USD | -2.15% |
| 2017 Q2 | 12.76 Million USD | 20.48% |
| 2017 Q3 | 11.51 Million USD | -9.75% |
| 2016 Q4 | 10.82 Million USD | 9.91% |
| 2016 Q1 | 9.68 Million USD | 1.94% |
| 2016 Q2 | 10.74 Million USD | 10.87% |
| 2016 Q3 | 9.84 Million USD | -8.31% |
| 2016 FY | 41.09 Million USD | 14.54% |
| 2015 Q4 | 9.5 Million USD | -3.34% |
| 2015 Q3 | 9.83 Million USD | 17.57% |
| 2015 Q2 | 8.36 Million USD | 2.14% |
| 2015 Q1 | 8.18 Million USD | -2.87% |
| 2015 FY | 35.88 Million USD | 3.37% |
| 2014 Q3 | 8.51 Million USD | -4.74% |
| 2014 FY | 34.71 Million USD | 9.67% |
| 2014 Q1 | 8.83 Million USD | 5.8% |
| 2014 Q4 | 8.42 Million USD | -1.0% |
| 2014 Q2 | 8.93 Million USD | 1.2% |
| 2013 Q4 | 8.34 Million USD | 10.28% |
| 2013 Q3 | 7.57 Million USD | -5.88% |
| 2013 Q2 | 8.04 Million USD | 4.59% |
| 2013 Q1 | 7.69 Million USD | -1.61% |
| 2013 FY | 31.65 Million USD | -2.19% |
| 2012 FY | 32.36 Million USD | -32.06% |
| 2012 Q1 | 8.91 Million USD | -12.32% |
| 2012 Q2 | 8.03 Million USD | -9.91% |
| 2012 Q3 | 7.59 Million USD | -5.38% |
| 2012 Q4 | 7.81 Million USD | 2.86% |
| 2011 Q3 | 11.82 Million USD | -1.71% |
| 2011 FY | 47.62 Million USD | -6.89% |
| 2011 Q4 | 10.16 Million USD | -14.05% |
| 2011 Q1 | 13.59 Million USD | 0.77% |
| 2011 Q2 | 12.03 Million USD | -11.48% |
| 2010 Q4 | 13.49 Million USD | 12.92% |
| 2010 Q2 | 12.78 Million USD | -1.04% |
| 2010 Q3 | 11.94 Million USD | -6.57% |
| 2010 Q1 | 12.92 Million USD | 1.76% |
| 2010 FY | 51.15 Million USD | 2.2% |
| 2009 Q2 | 11.64 Million USD | -17.78% |
| 2009 Q3 | 11.15 Million USD | -4.22% |
| 2009 Q4 | 12.69 Million USD | 13.87% |
| 2009 FY | 50.04 Million USD | -26.83% |
| 2009 Q1 | 14.16 Million USD | 16.51% |
| 2008 Q2 | 13.98 Million USD | 3.4% |
| 2008 Q4 | 12.15 Million USD | -20.36% |
| 2008 Q3 | 15.26 Million USD | 9.12% |
| 2008 Q1 | 13.52 Million USD | 5.89% |
| 2008 FY | 68.4 Million USD | 31.56% |
| 2007 Q4 | 12.77 Million USD | 6.42% |
| 2007 Q3 | 12 Million USD | -9.91% |
| 2007 Q1 | 13.89 Million USD | -4.05% |
| 2007 Q2 | 13.32 Million USD | -4.14% |
| 2007 FY | 51.99 Million USD | 3.81% |
| 2006 FY | 50.08 Million USD | 21.02% |
| 2006 Q1 | 10.46 Million USD | -3.17% |
| 2006 Q2 | 11.83 Million USD | 13.02% |
| 2006 Q3 | 13.29 Million USD | 12.39% |
| 2006 Q4 | 14.48 Million USD | 8.91% |
| 2005 Q4 | 10.81 Million USD | 7.84% |
| 2005 Q2 | 11.07 Million USD | 16.84% |
| 2005 FY | 41.38 Million USD | 16.8% |
| 2005 Q1 | 9.47 Million USD | 0.12% |
| 2005 Q3 | 10.02 Million USD | -9.44% |
| 2004 FY | 35.43 Million USD | 15.47% |
| 2004 Q3 | 9.14 Million USD | 3.65% |
| 2004 Q1 | 8 Million USD | 14.39% |
| 2004 Q4 | 9.46 Million USD | 3.5% |
| 2004 Q2 | 8.82 Million USD | 10.23% |
| 2003 Q1 | 7.99 Million USD | -19.68% |
| 2003 FY | 30.68 Million USD | -28.75% |
| 2003 Q4 | 6.99 Million USD | -9.43% |
| 2003 Q3 | 7.72 Million USD | -3.1% |
| 2003 Q2 | 7.97 Million USD | -0.31% |
| 2002 Q3 | 10.46 Million USD | -8.34% |
| 2002 Q2 | 11.42 Million USD | 1.78% |
| 2002 Q1 | 11.22 Million USD | -3.13% |
| 2002 FY | 43.06 Million USD | 11.87% |
| 2002 Q4 | 9.95 Million USD | -4.91% |
| 2001 Q4 | 11.58 Million USD | 7.1% |
| 2001 Q3 | 10.81 Million USD | 21.94% |
| 2001 Q2 | 8.87 Million USD | 22.72% |
| 2001 Q1 | 7.22 Million USD | 7.18% |
| 2001 FY | 38.49 Million USD | 55.94% |
| 2000 Q3 | 6.94 Million USD | 25.91% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | 24.68 Million USD | 154.06% |
| 2000 Q2 | 5.51 Million USD | 0.0% |
| 2000 Q4 | 6.74 Million USD | -2.88% |
| 1999 FY | 9.71 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -429.694% |
| Alpha Teknova, Inc. | 45.85 Million USD | 4.675% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 77.694% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 2.539% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 72.542% |
| Cosmos Health Inc. | 26.18 Million USD | -66.974% |
| Journey Medical Corporation | 54.59 Million USD | 19.927% |
| Embecta Corp. | 528.4 Million USD | 91.727% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 83.922% |
| Dynavax Technologies Corporation | 219.14 Million USD | 80.052% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 92.591% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 86.606% |
| PainReform Ltd. | 9.58 Million USD | -356.125% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -233.08% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -233.08% |
| SCYNEXIS, Inc. | 51.84 Million USD | 15.686% |
| Safety Shot Inc | 12.1 Million USD | -260.992% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -1324.318% |
| Procaps Group, S.A. | 199.47 Million USD | 78.085% |
| Theratechnologies Inc. | 72.75 Million USD | 39.916% |
| Harrow Health, Inc. | 89.97 Million USD | 51.413% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -362.788% |
| Biofrontera Inc. | 39.95 Million USD | -9.4% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 91.736% |
| Cronos Group Inc. | 96.7 Million USD | 54.797% |
| OptiNose, Inc. | 85.1 Million USD | 48.632% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 81.167% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -11.652% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 557.222% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 86.084% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -349.242% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -1.567% |
| Radius Health, Inc. | 265.92 Million USD | 83.561% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -215.816% |
| ProPhase Labs, Inc. | 37.85 Million USD | -15.489% |
| Phibro Animal Health Corporation | 260.29 Million USD | 83.206% |
| Procaps Group S.A. | 187.24 Million USD | 76.654% |
| Alvotech | 285.43 Million USD | 84.685% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -344.936% |
| Viatris Inc. | 5.96 Billion USD | 99.267% |
| Rockwell Medical, Inc. | 15.37 Million USD | -184.344% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 26.947% |
| SIGA Technologies, Inc. | 22.04 Million USD | -98.317% |
| Tilray Brands, Inc. | 251.35 Million USD | 82.608% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 10.855% |
| Shineco, Inc. | 17.94 Million USD | -143.564% |
| PetIQ, Inc. | 192.72 Million USD | 77.317% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -995.302% |
| Incannex Healthcare Limited | 30.05 Million USD | -45.46% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 97.262% |
| Alimera Sciences, Inc. | 62.64 Million USD | 30.213% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -5633.175% |
| Assertio Holdings, Inc. | 368.58 Million USD | 88.14% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -642.749% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -145.472% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -106.505% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -107.75% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 73.501% |
| Hempacco Co., Inc. | 7.59 Million USD | -475.466% |
| Talphera, Inc. | 11.99 Million USD | -264.474% |
| Alvotech | 285.43 Million USD | 84.685% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 68.933% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 87.325% |
| Currenc Group, Inc. | 24 Million USD | -82.13% |
| Kamada Ltd. | 45.42 Million USD | 3.767% |
| Indivior PLC | 911 Million USD | 95.201% |
| Evoke Pharma, Inc. | 12.4 Million USD | -252.266% |
| Flora Growth Corp. | 10.57 Million USD | -313.224% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -107.75% |
| Evolus, Inc. | 189.75 Million USD | 76.963% |
| HUTCHMED (China) Limited | 436.23 Million USD | 89.979% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 71.638% |
| Akanda Corp. | 3.48 Million USD | -1154.913% |